Prevalence and Factors Associated With Sleep Disorders in Inflammatory Bowel Disease
Launched by CHU DE REIMS · May 28, 2024
Trial Information
Current as of February 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how common sleep disorders are in people who have inflammatory bowel diseases (IBD), like Crohn's disease and ulcerative colitis. These conditions can cause inflammation in the digestive system, leading to symptoms like abdominal pain and diarrhea, which can significantly impact a person's quality of life. The researchers want to understand how these sleep issues are related to the patients' IBD symptoms and treatments, as many previous studies have shown that people with IBD often have trouble sleeping.
To participate in the trial, you need to be an adult patient diagnosed with Crohn's disease or ulcerative colitis and visiting a gastroenterology unit for care. Unfortunately, if you already have a known sleep disorder, you won't be eligible for this study. If you decide to join, you can expect to help researchers gather important information that could lead to better support and treatment for sleep problems in IBD patients, ultimately aiming to improve your overall quality of life. The trial is currently recruiting participants of all genders who are between the ages of 65 to 74.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients with Crohn's disease (CD) or ulcerative colitis (UC) presenting for consultation or hospitalization in Gastroenterology unit
- Exclusion Criteria:
- • Patients with an identified sleep pathology
About Chu De Reims
Chu de Reims, or the University Hospital of Reims, is a leading healthcare institution in France dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent clinical trial sponsor, Chu de Reims focuses on a wide range of therapeutic areas, fostering collaboration between multidisciplinary teams of healthcare professionals and researchers. The hospital is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring that all trials are designed to deliver reliable data while prioritizing patient safety and well-being. Through its robust research infrastructure, Chu de Reims aims to contribute significantly to the advancement of medical knowledge and the development of new treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Reims, , France
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0